Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2015 Sep 24;35(11):2297–2306. doi: 10.1161/ATVBAHA.115.305043

Figure 2.

Figure 2

Inducible pluripotent stem cell (iPSC)-based therapies for cardiovascular disease (CVD). Patient-derived fibroblasts can be reprogrammed into iPSCs and differentiated into endothelial (EC)-like cells for cell-based therapies of CVD. The processes of cellular reprogramming and endothelial differentiation involve dynamic changes in the epigenetic landscape.